XML 136 R113.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details) - USD ($)
$ in Millions
 1 Months Ended 12 Months Ended
Feb. 28, 2017
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Segment Reporting Information [Line Items]        
Interest income   $ 385 $ 328 $ 289
Interest expense   (754) (693) (672)
Equity income from affiliates   42 86 205
Depreciation and amortization   (4,637) (5,441) (6,375)
Research and development   (10,208) (10,124) (6,704)
Restructuring costs   (776) (651) (619)
Loss on extinguishment of debt   (191)    
Charge related to the settlement of worldwide Keytruda patent litigation $ (80) 0 (625) 0
Foreign currency devaluation related to Venezuela   0 0 (876)
Net charge related to the settlement of Vioxx shareholder class action litigation   0 0 680
Income Before Taxes   6,521 4,659 5,401
Total segment profits        
Segment Reporting Information [Line Items]        
Equity income from affiliates   (7) 105 70
Depreciation and amortization   (212) (183) (100)
Income Before Taxes   24,420 23,687 23,231
Total segment profits | Pharmaceutical segment        
Segment Reporting Information [Line Items]        
Equity income from affiliates   (7) 105 70
Depreciation and amortization   (125) (160) (82)
Income Before Taxes   22,586 22,180 21,658
Total segment profits | Other segments        
Segment Reporting Information [Line Items]        
Equity income from affiliates   0 0 0
Depreciation and amortization   (87) (23) (18)
Income Before Taxes   1,834 1,507 1,573
Other profits        
Segment Reporting Information [Line Items]        
Income Before Taxes   26 481 810
Unallocated        
Segment Reporting Information [Line Items]        
Interest income   385 328 289
Interest expense   (754) (693) (672)
Equity income from affiliates   49 (19) 135
Depreciation and amortization   (1,378) (1,585) (1,573)
Research and development   (9,355) (9,084) (5,871)
Amortization of purchase accounting adjustments   (3,056) (3,692) (4,816)
Restructuring costs   (776) (651) (619)
Loss on extinguishment of debt   (191) 0 0
Gain on sale of certain migraine clinical development programs   0 100 250
Charge related to the settlement of worldwide Keytruda patent litigation   0 (625) 0
Gain on divestiture of certain ophthalmic products   0 0 147
Foreign currency devaluation related to Venezuela   0 0 (876)
Net charge related to the settlement of Vioxx shareholder class action litigation   0 0 (680)
Other unallocated, net   $ (2,849) $ (3,588) $ (4,354)